MCID: SCL017
MIFTS: 41

Sclerosing Hemangioma malady

Categories: Cancer diseases

Aliases & Classifications for Sclerosing Hemangioma

Aliases & Descriptions for Sclerosing Hemangioma:

Name: Sclerosing Hemangioma 12 14 69
Cutaneous Fibrous Histiocytoma 69
Sclerosing Haemangioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:495
SNOMED-CT 64 134302009 72079004
UMLS 69 C1509148

Summaries for Sclerosing Hemangioma

MalaCards based summary : Sclerosing Hemangioma, also known as cutaneous fibrous histiocytoma, is related to papilloma and pulmonary sclerosing hemangioma. An important gene associated with Sclerosing Hemangioma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Arf6 trafficking events and Cell adhesion_Cadherin-mediated cell adhesion. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and liver, and related phenotypes are endocrine/exocrine gland and neoplasm

Wikipedia : 71 Benign fibrous histiocytomas (also known as dermal dendrocytoma,dermatofibroma,fibrous... more...

Related Diseases for Sclerosing Hemangioma

Diseases related to Sclerosing Hemangioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 172)
id Related Disease Score Top Affiliating Genes
1 papilloma 29.4 CTNNB1 MUC1 PGR
2 pulmonary sclerosing hemangioma 12.2
3 fibrous histiocytoma 11.3
4 hemangioma 10.7
5 avian influenza 10.3 MUC1 NKX2-1
6 trombiculiasis 10.3 CHGA MUC1
7 skeletal-extraskeletal angiomatosis 10.3 MUC1 SYP
8 breast secretory carcinoma 10.3 CHGA MUC1
9 gastrointestinal system benign neoplasm 10.3 CHGA NKX2-1
10 peroneal nerve paralysis 10.3 CHGA SYP
11 autosomal recessive stickler syndrome 10.3 MUC1 SYP
12 thymus small cell carcinoma 10.3 CHGA SYP
13 corneal intraepithelial neoplasm 10.3 MUC1 SYP
14 brain stem ependymoma 10.3 CHGA SYP
15 non specific chronic endometritis 10.3 CHGA SYP
16 extrahepatic biliary papillomatosis 10.3 CHGA SYP
17 kidney disease 10.3 NKX2-1 SYP
18 epithelioid malignant peripheral nerve sheath tumor 10.3 CHGA SYP
19 bone deterioration disease 10.3 NKX2-1 SYP
20 chondroblastoma 10.3 MUC1 NKX2-1
21 cartilage cancer 10.3 CHGA SYP
22 jejunal neuroendocrine tumor 10.3 CHGA SYP
23 agenesis and aplasia of uterine body 10.3 NKX2-1 SFTPB
24 renal pelvis adenocarcinoma 10.3 CHGA SYP
25 behcet's syndrome arthropathy 10.3 MUC1 SYP
26 barre-lieou syndrome 10.2 CHGA SYP
27 aneurysm of sinus of valsalva 10.2 MUC1 SYP
28 perineural angioma 10.2 CHGA SYP
29 gastric duplication cysts 10.2 CHGA SYP
30 diffuse cutaneous mastocytosis 10.2 CHGA SYP
31 gliofibroma 10.2 CHGA SYP
32 pelvic inflammatory disease 10.2 MUC1 SYP
33 adult botryoid rhabdomyosarcoma 10.2 CHGA SYP
34 superior vena cava syndrome 10.2 CHGA SYP
35 duodenal obstruction 10.2 NKX2-1 SYP
36 thymoma 10.2 MUC1 SYP
37 gestational trophoblastic neoplasm 10.2 MUC1 SYP
38 lacrimal gland mucoepidermoid carcinoma 10.2 MUC1 PGR
39 fragile x-associated tremor/ataxia syndrome 10.2 CHGA SYP
40 hepatorenal syndrome 10.2 CHGA SYP
41 acalculous cholecystitis 10.2 CHGA SYP
42 cervical lymphoepithelioma-like carcinoma 10.2 MUC1 PGR
43 piussan lenaerts mathieu syndrome 10.2 CHGA SYP
44 exotropia 10.2 MUC1 PGR
45 marfanoid hypermobility syndrome 10.2 MUC1 PGR
46 brain stem astrocytic neoplasm 10.2 CHGA SYP
47 breast pericanalicular fibroadenoma 10.2 NKX2-1 PGR
48 anal squamous cell carcinoma 10.2 CHGA SYP
49 uterine corpus myxoid leiomyosarcoma 10.2 CHGA SYP
50 calcific tendinitis 10.2 CHGA SYP

Graphical network of the top 20 diseases related to Sclerosing Hemangioma:



Diseases related to Sclerosing Hemangioma

Symptoms & Phenotypes for Sclerosing Hemangioma

MGI Mouse Phenotypes related to Sclerosing Hemangioma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.43 AR CHGA CTNNB1 CTNND1 NKX2-1 PGR
2 neoplasm MP:0002006 9.02 PGR AR CTNNB1 CTNND1 NKX2-1

Drugs & Therapeutics for Sclerosing Hemangioma

Drugs for Sclerosing Hemangioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
4
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
6
Dactinomycin Approved Phase 3 50-76-0 2019 457193
7
Epirubicin Approved Phase 3 56420-45-2 41867
8
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
9
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
10
Lenograstim Approved Phase 3,Phase 2 135968-09-1
11
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
12
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
13 Alkylating Agents Phase 3,Phase 2,Phase 1
14 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
15 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
16 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
17 Isophosphamide mustard Phase 3,Phase 2,Phase 1
18 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
19 Anti-Infective Agents Phase 3,Phase 2,Phase 1
20 Antimitotic Agents Phase 3,Phase 2,Phase 1
21 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
22 Antirheumatic Agents Phase 3,Phase 2,Phase 1
23 Etoposide phosphate Phase 3,Phase 2
24 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
25 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
26
Indinavir Approved Phase 2 150378-17-9 5362440
27
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
28
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
29
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
30
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
31
Bevacizumab Approved, Investigational Phase 2 216974-75-3
32
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
33
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
34
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
35
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
36
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
37
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
38
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
39
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
40
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
41
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
42
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
43
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
44
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
45
leucovorin Approved, Nutraceutical Phase 2 58-05-9 54575, 6560146 143
46
Docetaxel Approved May 1996, Investigational Phase 2,Phase 1 114977-28-5 148124 9877265
47
Camptothecin Experimental Phase 2 7689-03-4
48 Anti-HIV Agents Phase 2
49 Anti-Retroviral Agents Phase 2
50 Antiviral Agents Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 62)
id Name Status NCT ID Phase
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Unknown status NCT00346164 Phase 3
3 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3
4 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
5 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3
6 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3
7 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3
8 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
10 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3
11 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
12 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
13 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3
14 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
15 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2
16 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2
17 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2
18 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2
19 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2
20 Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Completed NCT00887809 Phase 2
21 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2
22 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
23 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2
24 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2
25 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2
26 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Completed NCT00085475 Phase 2
27 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2
28 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2
29 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2
30 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2
31 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2
32 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2
33 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2
34 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2
35 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
36 To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Recruiting NCT01962103 Phase 1, Phase 2
37 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2
38 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2
39 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2
40 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2
41 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma Active, not recruiting NCT00667342 Phase 2
42 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Active, not recruiting NCT01653028 Phase 2
43 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Not yet recruiting NCT03123276 Phase 1, Phase 2
44 Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Not yet recruiting NCT02923778 Phase 2
45 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2
46 Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Terminated NCT00740597 Phase 2
47 Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery Completed NCT00450736 Phase 1
48 Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors Completed NCT00413322 Phase 1
49 Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00030784 Phase 1
50 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1

Search NIH Clinical Center for Sclerosing Hemangioma

Genetic Tests for Sclerosing Hemangioma

Anatomical Context for Sclerosing Hemangioma

MalaCards organs/tissues related to Sclerosing Hemangioma:

39
Lung, Skin, Liver, Thyroid, Lymph Node, Endothelial, Tongue

Publications for Sclerosing Hemangioma

Articles related to Sclerosing Hemangioma:

(show top 50) (show all 167)
id Title Authors Year
1
Sclerosing hemangioma: A diagnostic dilemma in fine needle aspiration cytology. ( 27168758 )
2016
2
Preoperative Diagnosis in 46 Cases of Pulmonary Sclerosing Hemangioma. ( 27231179 )
2016
3
Ectopic ACTH syndrome caused by pulmonary carcinoid tumor mimicking long-standing sclerosing hemangioma. ( 26828249 )
2016
4
Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung. ( 27601661 )
2016
5
Co-occurrence of bronchial papilloma and pulmonary sclerosing hemangioma in a male. ( 27812454 )
2016
6
Pulmonary Hilar Tumor: An Unusual Presentation of Sclerosing Hemangioma. ( 27761142 )
2016
7
Sclerosing hemangioma of the lung showing strong FDG avidity on PET scan: Case report and review of the current literature. ( 27222778 )
2016
8
Clinical case report: Sclerosing hemangioma of the liver, a rare but great mimicker. ( 27257450 )
2016
9
Sclerosing hemangioma of the lung. ( 26223076 )
2015
10
Incidental finding of a sclerosing hemangioma in a Caucasian woman. ( 26193226 )
2015
11
Bone metastasis in pulmonary sclerosing hemangioma. ( 26552471 )
2015
12
Multiple hepatic sclerosing hemangioma mimicking metastatic liver tumor successfully treated by laparoscopic surgery: Report of a case. ( 25679307 )
2015
13
Sclerosing Hemangioma of the Lung Mimicking Pulmonary Metastasis. ( 25762452 )
2015
14
The significance of p40 expression in sclerosing hemangioma of lung. ( 25130377 )
2014
15
Pulmonary sclerosing hemangioma with lymph node metastasis: A case report and literature review. ( 24944657 )
2014
16
A rare tumor of the lung: pulmonary sclerosing hemangioma (pneumocytoma). ( 23290153 )
2013
17
18F-FDG PET/CT features of pulmonary sclerosing hemangioma. ( 22291338 )
2013
18
A hepatic sclerosed hemangioma with significant morphological change over a period of 10 years: a case report. ( 23714181 )
2013
19
A sclerosing hemangioma of the liver. ( 24459649 )
2013
20
Diagnosis of sclerosing hemangioma of lung: don't rely on fine-needle aspiration cytology diagnosis alone. ( 24518736 )
2013
21
Cytologic features of sclerosing hemangioma of the lung on crush preparations. ( 21710650 )
2013
22
Synchronous occurrence of breast cancer and pulmonary sclerosing hemangioma: management and review of the literature. ( 23838116 )
2013
23
Unusual coexistence of pulmonary sclerosing hemangioma and pericardial cyst. ( 24887810 )
2013
24
Pulmonary sclerosing hemangioma: a unique epithelial neoplasm of the lung (report of 26 cases). ( 23587094 )
2013
25
Histogenesis of pulmonary sclerosing hemangioma and significance of P63 expression. ( 23910931 )
2013
26
Pneumocytoma (formerly known as sclerosing hemangioma of the lung): a rare cause of chest pain. ( 23380035 )
2013
27
Pulmonary sclerosing hemangioma presenting with dense spindle stroma cells: a potential diagnostic pitfall. ( 23227905 )
2012
28
A case of pulmonary sclerosing hemangioma with low (18)FDG uptake in PET. ( 22740968 )
2012
29
Pulmonary sclerosing hemangioma: report of two cases. ( 22943472 )
2012
30
Fine-needle aspiration diagnosis of sclerosing hemangioma (pneumocytoma): Report of a case and review of the literature. ( 22645055 )
2012
31
In pulmonary sclerosing hemangioma expression of I^-catenin, Axin, and C-myc differs between the two cell types. ( 22614067 )
2012
32
Napsin A is differentially expressed in sclerosing hemangiomas of the lung. ( 23194051 )
2012
33
Sclerosing hemangioma of the lung manifesting as a cystic lesion with an air-fluid level. ( 22832056 )
2012
34
Treatment of 28 patients with sclerosing hemangioma (SH) of the lung. ( 22515818 )
2012
35
Pulmonary sclerosing hemangioma with pleural dissemination: report of a case. ( 21264765 )
2011
36
Pulmonary sclerosing hemangioma in a 21-year-old male with metastatic hereditary non-polyposis colorectal cancer: report of a case. ( 21645337 )
2011
37
F-18 FDG PET/CT in evaluation of pulmonary sclerosing hemangioma. ( 21467848 )
2011
38
Pulmonary sclerosing hemangioma: pitfalls in management. ( 21471259 )
2011
39
Sclerosing hemangioma in the liver. ( 22102394 )
2011
40
Surgery for Pulmonary Sclerosing Hemangioma: Lobectomy versus Limited Resection. ( 22263122 )
2011
41
Coexistence of pulmonary sclerosing hemangioma and primary adenocarcinoma in the same nodule of lung. ( 21599956 )
2011
42
A case of pulmonary sclerosing hemangioma surrounded by giant cystic change on high-resolution computed tomography. ( 20634757 )
2011
43
Determination of clonal status of pulmonary sclerosing hemangioma with X-chromosome inactivation mosaicism and polymorphism of phosphoglycerate kinase and androgen receptor genes. ( 20422318 )
2011
44
A case of sclerosing hemangioma forming a pedunculated mass. ( 21881332 )
2011
45
Microscopic sclerosing hemangioma diagnosed by histopathological examination after lung cancer surgery. ( 21881377 )
2011
46
Comparison of genetic and epigenetic alterations at 11 tumor suppressor loci in pulmonary sclerosing hemangioma and adenocarcinoma. ( 21649526 )
2011
47
So-called sclerosing hemangioma of lung: current concept. ( 20123460 )
2010
48
Large masses with diffuse calcification: pulmonary sclerosing hemangioma. ( 20732478 )
2010
49
A case of sclerosing hemangioma evaluated with diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography. ( 21057447 )
2010
50
Multiple FDG-avid sclerosing hemangiomas mimicking pulmonary metastases in a case of soft tissue sarcoma. ( 20675249 )
2010

Variations for Sclerosing Hemangioma

Expression for Sclerosing Hemangioma

Search GEO for disease gene expression data for Sclerosing Hemangioma.

Pathways for Sclerosing Hemangioma

GO Terms for Sclerosing Hemangioma

Biological processes related to Sclerosing Hemangioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 in utero embryonic development GO:0001701 9.61 AR CTNNB1 MUC1
2 adherens junction organization GO:0034332 9.46 CTNNB1 CTNND1
3 epithelial tube branching involved in lung morphogenesis GO:0060441 9.4 CTNNB1 NKX2-1
4 cellular process GO:0009987 9.37 AR CTNNB1
5 entry of bacterium into host cell GO:0035635 9.32 CTNNB1 CTNND1
6 Leydig cell differentiation GO:0033327 9.26 AR NKX2-1
7 epithelial cell differentiation involved in prostate gland development GO:0060742 9.16 AR CTNNB1
8 positive regulation of epithelial cell proliferation involved in prostate gland development GO:0060769 8.96 AR CTNNB1
9 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 8.62 AR PGR

Molecular functions related to Sclerosing Hemangioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.43 AR CTNNB1 NKX2-1
2 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 9.32 AR PGR
3 enzyme binding GO:0019899 9.26 AR CTNNB1 NKX2-1 PGR
4 steroid binding GO:0005496 9.16 AR PGR
5 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000978 8.92 AR CTNNB1 MUC1 PGR

Sources for Sclerosing Hemangioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....